WP
RVMD icon

Woodline Partners’s Revolution Medicines RVMD Stock Holding History

Woodline Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244M Buy
2,506,570
+5,675
+0.2% +$573K 0.92% 9
2025
Q4 		$199M Sell
2,500,895
-414,988
-14% -$27.2M 0.77% 15
2025
Q3 		$136M Buy
2,915,883
+311
+0% +$12.2K 0.64% 20
2025
Q2 		$107M Sell
2,915,572
-971,464
-25% -$37.3M 0.57% 16
2025
Q1 		$137M Buy
3,887,036
+1,323
+0% +$53.7K 0.89% 7
2024
Q4 		$170M Buy
3,885,713
+452,000
+13% +$22.8M 1.15% 5
2024
Q3 		$156M Buy
3,433,713
+142,922
+4% +$6.22M 1.31% 4
2024
Q2 		$128M Sell
3,290,791
-506,357
-13% -$18.9M 1.22% 6
2024
Q1 		$122M Buy
3,797,148
+837,108
+28% +$24.8M 1.13% 8
2023
Q4 		$84.9M Sell
2,960,040
-185,405
-6% -$4.46M 0.92% 18
2023
Q3 		$87.1M Sell
3,145,445
-615,930
-16% -$18.3M 1.02% 18
2023
Q2 		$101M Buy
3,761,375
+338,403
+10% +$8.3M 1.19% 12
2023
Q1 		$74.1M Buy
3,422,972
+2,972,957
+661% +$73.2M 1.01% 16
2022
Q4 		$10.7M Sell
450,015
-113,866
-20% -$2.42M 0.14% 195
2022
Q3 		$11.1M Buy
563,881
+300,082
+114% +$6.59M 0.16% 187
2022
Q2 		$5.14M Sell
263,799
-2,067,596
-89% -$40.2M 0.08% 256
2022
Q1 		$59.5M Sell
2,331,395
-598,643
-20% -$13M 0.97% 17
2021
Q4 		$73.7M Buy
2,930,038
+2,060,554
+237% +$58.1M 1.06% 13
2021
Q3 		$23.9M Buy
869,484
+17,892
+2% +$521K 0.39% 69
2021
Q2 		$27M Buy
851,592
+9,530
+1% +$333K 0.5% 49
2021
Q1 		$38.6M Buy
842,062
+34,932
+4% +$1.57M 0.86% 28
2020
Q4 		$32M Buy
807,130
+779,219
+2,792% +$30.8M 0.85% 29
2020
Q3 		$971K Buy
+27,911
New +$773K 0.03% 172
2020
Q2 		– Sell
-54,867
Closed -$1.2M – 182
2020
Q1 		$1.2M Buy
+54,867
New +$1.52M 0.09% 124

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Woodline Partners's RVMD Position: Q1 2026 in Review

Woodline Partners increased its Revolution Medicines (RVMD) stake by 0.23% in Q1 2026, buying an estimated $573K and bringing the position to 2,506,570 shares worth $244M. The position accounts for 0.92% of the portfolio, ranked #9.

Woodline Partners first reported a position in RVMD in Q1 2020 and has held it in 24 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Woodline Partners held 2,506,570 shares of Revolution Medicines worth $244M as of Q1 2026.
  • Woodline Partners bought 5,675 Revolution Medicines shares in Q1 2026, an estimated $573K.
  • Revolution Medicines made up 0.92% of Woodline Partners's portfolio in Q1 2026, its #9 holding.
  • Woodline Partners first reported a position in Revolution Medicines in Q1 2020 and has held it in 24 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.